Current Focus
Intellectual property filings are in progress for composition-of-matter and method-of-use coverage across the lead NET PAM candidate class, intranasal delivery strategy, and kinetic precision therapeutic framework.
Research Mission
Tracking progression from therapeutic framework construction through translational and clinical development phases.
Development Timeline
Therapeutic Framework
Core monograph completion covering kinetic mismatch hypothesis, NET PAM rationale, retrometabolic safety logic, intranasal deployment framing, and responder phenotype definition.
CompleteIntellectual Property
Composition-of-matter and method-of-use filings to protect candidate architecture, delivery strategy, and kinetic precision use framework.
In ProgressLead Compound Validation
Prioritization of lead candidates based on transporter turnover enhancement profile, selectivity behavior, and coupled transport integrity.
UpcomingPreclinical Validation
In-vitro and in-vivo translational studies confirming accelerated clearance signatures, preserved phasic separability, and acceptable safety margins.
FutureIND-Enabling Studies
GLP toxicology package, CMC readiness, and regulatory documentation for Investigational New Drug submission.
FutureClinical Development
First-in-human entry in biomarker-informed cohorts to characterize safety, exposure timing, and pharmacodynamic behavior.
FutureRegulatory Orientation
Program documentation is being structured for standard FDA and EMA neurotherapeutic pathways, with milestone gating based on data quality and reproducibility.